Last quarter (Q3 2022), ONO Pharmaceutical Co's total revenue was ¥122.32B, an increase of 25.64% from the same quarter last year. In Q3, ONO Pharmaceutical Co's net income was ¥33.32B. See ONO Pharmaceutical Co’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Mar 23	Mar 22	Mar 21	Mar 20	Mar 19
Total Revenue	¥ 318.97B	-	¥ 361.36B	¥ 309.28B	¥ 292.42B	¥ 288.63B
Cost of Revenue	¥ 79.89B	-	¥ 93.51B	¥ 85.57B	¥ 79.06B	¥ 83.83B
Gross Profit	¥ 239.08B	-	¥ 267.85B	¥ 223.71B	¥ 213.36B	¥ 204.81B
Operating Expense	¥ 137.57B	-	¥ 164.65B	¥ 125.38B	¥ 135.87B	¥ 142.79B
Operating Income	¥ 101.51B	-	¥ 103.20B	¥ 98.33B	¥ 77.49B	¥ 62.01B
Net Non Operating Interest Income Expense	¥ 1.57B	-	¥ 1.84B	¥ 2.56B	¥ 2.21B	¥ 3.13B
Other Income Expense	-	-	-	-	-	-
Pretax Income	¥ 103.08B	-	¥ 105.03B	¥ 100.89B	¥ 79.70B	¥ 65.14B
Tax Provision	¥ 24.15B	-	¥ 24.34B	¥ 25.39B	¥ 19.81B	¥ 13.46B
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	¥ 78.69B	-	¥ 80.52B	¥ 75.42B	¥ 59.70B	¥ 51.54B
Basic EPS	-	-	-	-	-	-
Diluted EPS	-	-	-	-	-	-
Basic Average Shares	-	-	-	-	-	-
Diluted Average Shares	-	-	-	-	-	-
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	¥ 217.46B	-	¥ 258.17B	¥ 210.95B	¥ 214.93B	¥ 226.62B
Net Income From Continuing And Discontinued Operation	¥ 78.69B	-	¥ 80.52B	¥ 75.42B	¥ 59.70B	¥ 51.54B
Normalized Income	¥ 78.69B	-	¥ 80.52B	¥ 75.42B	¥ 59.70B	¥ 51.54B
Interest Expense	¥ 945.00M	-	¥ 874.00M	¥ 137.00M	¥ 845.00M	¥ 150.00M
EBIT	¥ 104.02B	-	¥ 105.90B	¥ 101.03B	¥ 80.54B	¥ 65.29B
EBITDA	¥ 117.29B	¥ 161.90B	¥ 123.62B	¥ 116.85B	¥ 94.75B	¥ 75.91B

Currency in JPY

ONO Pharmaceutical Co Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing